TABLE 1.
P‐selectin inhibitors investigated for use in VTE and other disorders
| Agent | Drug class | MOA | Preclinical model evaluated | Completed clinical trials | Ongoing clinical trials | FDA approval |
|---|---|---|---|---|---|---|
| PSI−697 44 , 49 , 57 , 58 , 60 and PSI−421 48 | Small molecule | Selective P‐selectin small molecule antagonists |
PSI−697: VTE, SCD, atherosclerosis (arterial injury) PSI−421: VTE |
PSI−697: Smokers and Scleritis | No | |
| PSGL‐Ig 45 , 46 , 47 , 61 , 62 , 63 , 64 , 65 , 66 | Conjugate | A PSGL−1 trap | VTE, thrombolysis, restenosis, MI, liver transplantation, and ischemia/reperfusion | Phase II:MI size reduction, liver transplantation | No | |
| ARC5692, 51 ARC5690 51 , 67 | Aptamer | Pegylated anti‐P‐selectin aptamer | VTE, SCD | No | ||
| PEG40‐GSnP−6 (P‐G6) 54 , 55 | Glycomimetic | Pegylated glycomimetic of the N terminus of PSGL−1 | VTE | No | ||
| Inclacumab 68 , 69 , 70 , 71 | Antibody | Recombinant monoclonal antibody against P‐selectin | SCD | ACS; MI; Peripheral vascular disorders | Phase 3: VOC in SCD | No |
| Crizanlizumab 72 , 73 , 74 | Antibody | Monoclonal antibody against P‐selectin | SCD, myelofibrosis |
Phase 1/2: Myelofibrosis Phase 2: Priapism; RVCL Phase 2, 3, 4: SCD Phase 4 COVID−19 |
Yes: SCD, VOC | |
| SelK2 56 | Antibody | Monoclonal antibody against PSGL−1 | VTE | DVT, COPD | No |